Deutsche Bank analyst James Shin raised the firm’s price target on Gilead (GILD) to $135 from $120 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $140 from $126 at BofA
- Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology?
- Tesla disbands supercomputer team, Trade Desk Q2 spurs downgrades: Morning Buzz
- Gilead and Arcus Advance Promising Colorectal Cancer Study
- Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers